Vaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Decreased by Trexquant Investment LP

Trexquant Investment LP trimmed its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 17.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 66,249 shares of the company's stock after selling 13,689 shares during the quarter. Trexquant Investment LP owned approximately 0.05% of Vaxcyte worth $5,423,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Vaxcyte by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock valued at $979,184,000 after buying an additional 521,204 shares during the last quarter. State Street Corp boosted its stake in shares of Vaxcyte by 1.1% during the third quarter. State Street Corp now owns 3,405,743 shares of the company's stock valued at $389,174,000 after acquiring an additional 38,596 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of Vaxcyte by 3.0% during the fourth quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company's stock valued at $234,884,000 after acquiring an additional 82,997 shares during the last quarter. Geode Capital Management LLC increased its position in Vaxcyte by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company's stock worth $229,495,000 after purchasing an additional 102,106 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in Vaxcyte by 8.1% in the 4th quarter. Alliancebernstein L.P. now owns 1,779,362 shares of the company's stock valued at $145,659,000 after purchasing an additional 133,448 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Remove Ads

Insider Transactions at Vaxcyte

In other news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $86.22, for a total transaction of $689,760.00. Following the sale, the chief operating officer now directly owns 205,695 shares of the company's stock, valued at approximately $17,735,022.90. The trade was a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now directly owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,250 shares of company stock valued at $3,170,738 over the last quarter. Company insiders own 3.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Bank of America lowered their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 price target on shares of Vaxcyte in a report on Tuesday. Guggenheim restated a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, March 12th. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Finally, The Goldman Sachs Group reduced their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $136.50.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded down $2.66 during trading on Thursday, reaching $28.14. 720,017 shares of the stock were exchanged, compared to its average volume of 1,171,989. Vaxcyte, Inc. has a 12-month low of $27.80 and a 12-month high of $121.06. The firm's 50-day moving average price is $68.64 and its 200 day moving average price is $86.91. The firm has a market cap of $3.62 billion, a price-to-earnings ratio of -6.07 and a beta of 1.26.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. As a group, equities research analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.